| __timestamp | Apellis Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 21226345 |
| Thursday, January 1, 2015 | 13730311 | 87718074 |
| Friday, January 1, 2016 | 22978599 | 93831530 |
| Sunday, January 1, 2017 | 40303878 | 79419009 |
| Monday, January 1, 2018 | 105285576 | 132166913 |
| Tuesday, January 1, 2019 | 220968770 | 89124838 |
| Wednesday, January 1, 2020 | 299921000 | 65782137 |
| Friday, January 1, 2021 | 420869000 | 88845513 |
| Saturday, January 1, 2022 | 387236000 | 134715000 |
| Sunday, January 1, 2023 | 354387000 | 180142000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Apellis Pharmaceuticals, Inc. have been at the forefront of this race.
From 2014 to 2023, Apellis Pharmaceuticals has seen a staggering increase in R&D expenses, growing by over 4,000% from its initial spending. Intra-Cellular Therapies, while starting with a higher base, has also shown a robust growth of approximately 750% in the same period.
By 2023, Apellis Pharmaceuticals' R&D spending reached a peak, nearly doubling that of Intra-Cellular Therapies. This significant investment underscores Apellis' aggressive pursuit of groundbreaking treatments. Meanwhile, Intra-Cellular Therapies continues to maintain a steady upward trajectory, reflecting its strategic focus on sustainable innovation.
Analyzing R&D Budgets: Merck & Co., Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Xencor, Inc.